Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
58 hedge funds and large institutions have $42.6M invested in Aptose Biosciences, Inc. in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 17 closing their positions.
93% more call options, than puts
Call options by funds: $197K | Put options by funds: $102K
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 64 → 58 (-6)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
51% less capital invested
Capital invested by funds: $86.5M → $42.6M (-$43.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$1.42M |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$1.23M |
| 3 |
VC
Voss Capital
Houston,
Texas
|
+$1.01M |
| 4 |
Two Sigma Investments
New York
|
+$982K |
| 5 |
Millennium Management
New York
|
+$833K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.54M |
| 3 |
O
OrbiMed
New York
|
-$5.66M |
| 4 |
6CM
683 Capital Management
New York
|
-$2.28M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.2M |
APTO Hedge Fund Activity: Q4 2021 in Review
58 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2021, worth a combined $42.6M — down 51% from $86.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of APTO and 11 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 22 added.
The largest buyer was Carlson Capital, adding an estimated $1.42M. The largest seller was First Light Asset Management, exiting entirely with an estimated $9M sold.
- 58 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2021, down from 64 in Q3 2021.
- Funds reported $42.6M of Aptose Biosciences, Inc. stock for Q4 2021, down 51% quarter-over-quarter.
- 11 funds opened new Aptose Biosciences, Inc. positions in Q4 2021 and 17 closed out, a net change of -6 holders.
- The largest Aptose Biosciences, Inc. buyer in Q4 2021 was Carlson Capital, an estimated $1.42M added.
- The largest Aptose Biosciences, Inc. seller in Q4 2021 was First Light Asset Management, an estimated $9M sold.
Based on aggregated 13F filings for Q4 2021.